Evaluation of early efficacy endpoints for proof-of-concept trials

Journal of Biopharmaceutical Statistics

Volumn 23, Issue 2, 2013, Pages 413-424

  Chen, Cong ^a   Sun, Linda ^a   Li, Chih Lin ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Benefit cost ratio; Decision analysis; Expected power; Oncology

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ANALYTICAL ERROR; ARTICLE; BINOMIAL DISTRIBUTION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EFFECT SIZE; EVALUATION; HUMAN; LUNG NON SMALL CELL CANCER; NORMAL DISTRIBUTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; TUMOR VOLUME; UNCERTAINTY;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DRUG DISCOVERY; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS;

EID: 84874491035     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2011.616969     Document Type: Article

References (17)

1. Biomarker Definitions Working Group. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 69:89-95.
2. Burzykowski, T., Molenberghs, G., Buyse, M. (2005). The Evaluation of Surrogate Endpoints. New York, NY: Springer.
3. Buyse, M., Molenberghs, G. (1998). The validation of surrogate endpoints in randomized experiments. Biometrics 54:1014-1029.
4. Buyse, M., Piedbois, P. (1996). On the relationship between response to treatment and survival time. Statistics in Medicine 15:2797-2812.
5. Buyse, M., et al. (2000). The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1:49-67.
6. Chen, C., Beckman, B. (2009a). Optimal cost-effective designs of proof of concept trials and associated GoYNo Go decisions. Journal of Biopharmaceutical Statistics 19(2):424-436.
7. Chen, C., Beckman, R. A. (2009b). Optimal cost-effective GoYNo Go decisions in late-stage oncology drug development. Statistics in Biopharmaceutical Research 1:159-169.
8. Chen, C., Wang, H. W. (2005). Proportion of treatment effect. Encyclopedia of Biopharmaceutical Statistics 1(1):1-5.
9. Fleming, T. R. (2005). Objective response rate as a surrogate endpoint: A commentary. Journal of Clinical Oncology 23:4845-4846.
10. Mackenzie, T., Abrahamowicz, M. (2005). Using categorical markers as auxiliary variables in log-rank test and hazard ratio estimation. Canadian Journal of Statistics 33:201-219.
11. Molenberghs, G., et al. (2002). Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Controlled Clinical Trials 23:607-625.
12. Prentice, R. L. (1989). Surrogate endpoints in clinical trials: Definitions and operational criteria. Statistics in Medicine 8:431-440.
13. Robins, J. M. (1993). Information recovery and bias adjustment in proportional hazards regression analysis of randomized trials using surrogate markers. Proceedings of Biopharmaceutical Section, American Statistical Association. pp. 24-33.
14. Robins, J. M., Finkelstein, D. M. (2000). Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 56:779-788.
15. Sargent, D., Wieand, S., Haller, D. G., et al. (2005). Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 20, 898 patents on 18 randomized trials. Journal of Clinical Oncology 23:8664-8670.
16. Tang, P. A., Bentzen, S. M., Chen, E. X., Siu, L. L. (2007). Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. Journal of Clinical Oncology 25:4562-4568.
17. Whitehead, A. (2002). Meta-analysis of Controlled Clinical Trials. New York, NY: Wiley.